Phil Taylor, Author at

News/ News/ Oncology

Mirati heads for FDA verdict on KRAS drug with new data

Phil Taylor adagrasib, Amgen, asco, KRAS, Lumakras, Mirati, Non-small cell lung cancer 0 Comment

Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete

Mirati heads for FDA verdict on KRAS drug with new data

https://pharmaphorum.com/news/mirati-heads-for-fda-verdict-on-kras-drug-with-new-data/

News/ News/ Oncology

Roche trumpets new glofitamab data in lymphoma at ASCO

Phil Taylor bispecific antibody, diffuse B-Cell lymphoma, epcoritamab, glofitamab, non-Hodgkin lymphoma, Polivy, Roche 0 Comment

Roche will present the new data at next week’s ASCO congress showing that its bispecific antibody glofitamab can

Roche trumpets new glofitamab data in lymphoma at ASCO

https://pharmaphorum.com/news/roche-trumpets-new-glofitamab-data-in-lymphoma-at-asco/

News/ News/ Oncology

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Phil Taylor CAR-T therapies, Carvykti, EU, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, regulatory approval 0 Comment

Johnson & Johnson and Legend Biotech will arrive at next week’s ASCO congress with a new EU approval

J&J, Legend get EU nod for myeloma CAR-T Carvykti

https://pharmaphorum.com/news/jj-legend-get-eu-nod-for-myeloma-car-t-carvykti/

Digital/ News/ News

Akili partners with gaming giant Roblox on ADHD therapy delivery

Phil Taylor Akili Interactive, attention deficit hyperactivity disorder, digital, digital health, games for health, partnering, Roblox 0 Comment

Digital health company Akili Interactive has agreed a deal that could see its gamified therapy for attention-deficit hyperactivity

Akili partners with gaming giant Roblox on ADHD therapy delivery

https://pharmaphorum.com/news/akili-partners-with-gaming-giant-roblox-on-adhd-therapy-delivery/

News/ News/ R&D

Biotech founder arrested in US amid murder-for-hire investigation

Phil Taylor criminal investigation, Enochian Biosciences, immunology, Legal, Oncology, Serhat Gümrükcü 0 Comment

The co-founder of Los Angeles biotech Enochian Biosciences has been arrested in connection with a federal investigation into

Biotech founder arrested in US amid murder-for-hire investigation

https://pharmaphorum.com/news/biotech-founder-arrested-in-us-amid-murder-for-hire-investigation/

News/ News/ News/ Oncology/ Sales and Marketing

FDA clears new first-line use for Servier’s Tibsovo in AML

Phil Taylor acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo 0 Comment

Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma’s oncology business

FDA clears new first-line use for Servier’s Tibsovo in AML

https://pharmaphorum.com/news/fda-clears-new-first-line-use-for-serviers-tibsovo-in-aml/

News/ News/ Sales and Marketing

Lilly sets aside $2.1bn for domestic investments

Phil Taylor Eli Lilly, Indiana, investment, manufacturing 0 Comment

Eli Lilly’s home state of Indiana is set to benefit from a massive $2.1 billion investment by the

Lilly sets aside $2.1bn for domestic investments

https://pharmaphorum.com/news/lilly-sets-aside-2-1bn-for-domestic-investments/

Digital/ News/ News/ News/ R&D

Cumulus puts its digital biomarkers for CNS diseases to the test

Phil Taylor Alzheimer's disease, amyotrophic lateral sclerosis, Cumulus Neuroscience, dementia, digital, digital biomarker, digital health, neurology 0 Comment

Cumulus Neuroscience has started a pair of clinical trials to gauge the value of a panel of physiological

Cumulus puts its digital biomarkers for CNS diseases to the test

https://pharmaphorum.com/news/cumulus-puts-its-digital-biomarkers-for-cns-diseases-to-the-test/

Market Access/ News/ News/ News/ Oncology

Angle claims FDA okay for Parsortix liquid biopsy system

Phil Taylor Angle, breast cancer, diagnosis, liquid biopsy, Oncology, Parsortix, regulatory approval 0 Comment

After more than six years of development, Angle has scored an FDA approval for Parsortix as a diagnostic

Angle claims FDA okay for Parsortix liquid biopsy system

https://pharmaphorum.com/news/angle-claims-fda-okay-for-parsortix-liquid-biopsy-system/

Trending

About Phil Taylor

Posts by Phil Taylor:

Mirati heads for FDA verdict on KRAS drug with new data

Roche trumpets new glofitamab data in lymphoma at ASCO

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Akili partners with gaming giant Roblox on ADHD therapy delivery

Biotech founder arrested in US amid murder-for-hire investigation

FDA clears new first-line use for Servier’s Tibsovo in AML

Lilly sets aside $2.1bn for domestic investments

Cumulus puts its digital biomarkers for CNS diseases to the test

Angle claims FDA okay for Parsortix liquid biopsy system

Trending

About Phil Taylor

Posts by Phil Taylor:

Login